Zoetis Inc. (NYSE:ZTS) Shares Purchased by TCV Trust & Wealth Management Inc.

TCV Trust & Wealth Management Inc. raised its holdings in Zoetis Inc. (NYSE:ZTS) by 1.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,401 shares of the company’s stock after buying an additional 1,217 shares during the quarter. TCV Trust & Wealth Management Inc.’s holdings in Zoetis were worth $12,774,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. AMF Tjanstepension AB raised its stake in Zoetis by 23.4% during the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after purchasing an additional 20,001 shares during the period. Exchange Traded Concepts LLC increased its holdings in shares of Zoetis by 4,582.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 1,639 shares of the company’s stock worth $320,000 after buying an additional 1,604 shares during the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH purchased a new position in shares of Zoetis in the 3rd quarter worth $127,000. Oliver Luxxe Assets LLC acquired a new position in Zoetis in the third quarter valued at $206,000. Finally, Sapient Capital LLC grew its position in Zoetis by 212.7% during the third quarter. Sapient Capital LLC now owns 4,859 shares of the company’s stock valued at $949,000 after acquiring an additional 3,305 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ZTS. Morgan Stanley cut their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus decreased their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Piper Sandler cut their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus price target of $214.00.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Zoetis Stock Up 1.5 %

Shares of NYSE ZTS opened at $174.47 on Wednesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The stock’s 50-day simple moving average is $169.16 and its 200-day simple moving average is $179.15. The firm has a market cap of $78.72 billion, a price-to-earnings ratio of 32.80, a PEG ratio of 2.77 and a beta of 0.90.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.15%. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.